<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593173</url>
  </required_header>
  <id_info>
    <org_study_id>7905</org_study_id>
    <nct_id>NCT04593173</nct_id>
  </id_info>
  <brief_title>Diabetic Cardiomyopathy</brief_title>
  <acronym>CarDiab</acronym>
  <official_title>Diabetic Cardiomyopathy: Diagonostic Value of 2D and 3D Left Ventricular Strains in Echocardiography in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes represents one of the 10 leading causes of death in the world and concerns 5% of the&#xD;
      French population (&gt; 3.3 million patients). About 30% of diabetic patients will develop heart&#xD;
      failure. The specific and early identification of diabetic cardiomyopathy at a subclinical&#xD;
      stage (asymptomatic patients with normal LVEF) will thus make it possible to predict the risk&#xD;
      of the onset of heart failure and to strengthen their monitoring and further adapt their&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Actual">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of Value of 2D and 3D Left Ventricular Strains in Echocardiography in Type 2 of diabetic Patients</measure>
    <time_frame>The files analysed retrospectily from April 15, 2015 to April 30, 2019 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Diabetic Cardiomyopathies</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetic and hypertensive patients, treated in the Internal Medicine and Diabetology&#xD;
        Services of Strasbourg University Hospitals, between 04/15/2015 to 04/30/2019.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient (≥18 years old)&#xD;
&#xD;
          -  Type 2 diabetic and hypertensive subjects, cardiac asymptomatic, without myocardial&#xD;
             ischemia documented by Dobutamine stress ultrasound (ESD), having at least 1&#xD;
             additional CV risk factor among: dyslipidemia, active or stopped smoking for less than&#xD;
             3 years, family history (1st degree relationship) of major CV accident before age 60,&#xD;
             obliterating arteriopathy of the lower limbs and / or carotid atheroma, or&#xD;
             proteinuria.&#xD;
&#xD;
          -  Subject not having expressed his opposition, after information, to the reuse of his&#xD;
             data for the purposes of this research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who expressed his opposition to participating in the study&#xD;
&#xD;
          -  Valvular heart disease (moderate to severe valve disease), hypertrophic or dilated&#xD;
             (MVGi&gt; 95 g / m2 in women and MVGi&gt; 115 g / m2 in men), chronic pulmonary;&#xD;
&#xD;
          -  History of cardiotoxic chemotherapy;&#xD;
&#xD;
          -  Subject under legal protection, under guardianship or under guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samy TALHA, MD</last_name>
    <phone>33 3 69 55 13 68</phone>
    <email>samy.talha@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <phone>33 3 88 11 66 90</phone>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Physiologie et d'Explorations Fonctionnelles</name>
      <address>
        <city>Strasbourg</city>
        <state>Starsbourg</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samy TALHA, MD</last_name>
      <phone>33 3 69 55 13 68</phone>
      <email>samy.talha@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <phone>33 3 88 11 66 90</phone>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Samy TALHA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel ANDRES, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard GENY, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick OHLMANN, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Soraya EL GHANNUDI-ABDO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique PARIS-BOCKEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc-André GOLTZENE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Cardiomyopathy</keyword>
  <keyword>Diabetic Cardiomyopathies</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Left ventricle</keyword>
  <keyword>strain 2D and 3D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Diabetic Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

